ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024
A Nanographene-Porphyrin Hybrid for Near-Infrared-Ii Phototheranostics.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 39 citations in OpenAlex.
- Triply N-Confused Hexaphyrins(1.1.1.1.1.0) Synthesized From N-Confused Hexaphyrin(2.1.1.1.1.1): Aromaticity Modulation, Metal Coordination, and Photothermal Conversion.Angewandte Chemie (International ed. in English) · 2026Article
- Molecular Engineering of Porphyrins for Near-Infrared Bioimaging and Phototherapy.Chemical & biomedical imaging · 2026Review
- NIR-II photothermal-amplified triple catalysis of a spherical mesoporous iron single-atom nanozyme for potentiating ferroptosis-based tumor therapy.Journal of nanobiotechnology · 2026Article
- Advances in Second Near-Infrared Window Photothermal Agents and Photothermal Therapy for Tumors in Interdisciplinary Medical Research.Pharmaceutics · 2025Review
- NIR Driven Pd/Cerium Oxide Nano-Heterojunction for Enhanced Salvaging Sepsis Induced Acute Liver Injury via Reprogramming Redox Homeostasis in Synergy with Inducing Autophagy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A novel conjugated polymer synthesizedMaterials today. Bio · 2025Article
- Donor modulation brings all-in-one phototheranostics for NIR-II imaging-guided type-I photodynamic/photothermal synergistic cancer therapy.Chemical science · 2025Article
- Panchromatic PAH-Porphyrin Hybrids with a Step-Wise Increasing π-System.ChemistryOpen · 2025Article
- Manifold-Fused Porphyrin-Nanographene Conjugates.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024Article
- Recent advances of photoresponsive nanomaterials for diagnosis and treatment of acute kidney injury.Journal of nanobiotechnology · 2024Review
- A Nanographene-Porphyrin Hybrid for Near-Infrared-Ii Phototheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
Abstract
Photoacoustic imaging (PAI)-guided photothermal therapy (PTT) in the second near-infrared (NIR-II, 1000-1700 nm) window has been attracting attention as a promising cancer theranostic platform. Here, it is reported that the π-extended porphyrins fused with one or two nanographene units (NGP-1 and NGP-2) can serve as a new class of NIR-responsive organic agents, displaying absorption extending to ≈1000 and ≈1400 nm in the NIR-I and NIR-II windows, respectively. NGP-1 and NGP-2 are dispersed in water through encapsulation into self-assembled nanoparticles (NPs), achieving high photothermal conversion efficiency of 60% and 69%, respectively, under 808 and 1064 nm laser irradiation. Moreover, the NIR-II-active NGP-2-NPs demonstrated promising photoacoustic responses, along with high photostability and biocompatibility, enabling PAI and efficient NIR-II PTT of cancer in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.